| Drug Type Monoclonal antibody | 
| Synonyms TATX 26, TATX26 | 
| Target | 
| Action inhibitors | 
| Mechanism TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 12 Oct 2022 | |
| Solid tumor | Discovery | United States  | 01 Mar 2025 | |
| Solid tumor | Discovery | United States  | 01 Mar 2025 | |
| Solid tumor | Discovery | Belgium  | 01 Mar 2025 | 






